Boehringer increases its production capacities
After investing 70 million euros in R & D center, the German pharmaceutical group Boehringer Ingelheim strengthens its presence in France with the construction of a veterinary vaccine plant. This new operation represents an investment of €200 million and will generate a hundred jobs.
The new group will be located in Jonage, in the suburbs of Lyon, and will cover 15,000 square meters.
A strategic veterinary vaccine production site
The new plant will be dedicated primarily to the production of livestock vaccines against foot-and-mouth disease and bluetongue. In a second step, Boehringer Ingelheim could set up antigen banks, strategic vaccine reserves that could be activated quickly by governments in the event of an epidemic.
European food safety standards defined in France
The German group has based its decision to locate this new plant in France following the designation of the French National Agency for Food Safety and Food (ANSES) as the new "reference laboratory" of the European Union for fever foot.
This new investment, says Erick Lelouche, president of the animal health business in France, is a logical follow-up to the acquisition in 2017 of Merial, Sanofi's former animal health division.
Boehringer Ingelheim also strengthens its R & D in France
Vaccine formulation and packaging will be carried out at the nearby Lyon Porte-des-Alpes site (Saint-Priest), which has received an investment of 135 million euros.
This new investment confirms the strong commitment of the German group in France. Indeed, the company has dedicated more than 3 billion euros to R & D in 2017.